China Drug Makers Brace As Anti-Graft Campaign Impact Surfaces
Mixed Outlook
Executive Summary
Simcere, Hengrui, and Zai Lab are among the first Chinese pharma firms to report various forms of impact from the gathering storm of a national anti-corruption campaign launched in July in the healthcare and pharma sectors.